Subgroup Analysis

A subgroup analysis examines whether the effect of an intervention or exposure differs across specific subsets of participants, defined by baseline characteristics such as age, sex, disease severity, or comorbidities. It can reveal effect modification (interaction), where the intervention works differently in different patient groups, informing targeted treatment decisions.

The overall result of a trial or meta analysis may not apply equally to all patients. Some patients may benefit more from an intervention, while others may not benefit at all or may even be harmed. Subgroup analyses explore this heterogeneity, potentially identifying patient groups for whom an intervention is particularly effective or ineffective. However, subgroup analyses are often underpowered and subject to multiple comparison problems, making their results prone to false positives. The distinction between prespecified and post hoc subgroup analyses is critical for interpretation.

In a clinical trial, subgroup analyses divide the study population into two or more groups based on a baseline characteristic and estimate the treatment effect separately within each group. A formal test of interaction assesses whether the treatment effect differs significantly between subgroups, comparing it against a null hypothesis that the treatment effect is the same in all subgroups. This interaction test is more appropriate than simply noting that the treatment is significant in one subgroup and not another, which can be misleading due to differences in statistical power.

In meta analysis, subgroup analysis divides included studies into groups based on study level characteristics (such as study design, geographic region, or intervention type) and compares the pooled effects across groups. This approach can help explain between study heterogeneity and identify possible moderating factors, but because the comparison is between studies rather than between randomized groups, it is observational and open to confounding by other study characteristics.

Prespecified subgroup analyses, listed in the protocol before data collection, are more credible than post hoc analyses conducted after seeing the data. The number of subgroup analyses should be limited to reduce the risk of false positives, and the subgroup variables should be selected based on biological plausibility or prior evidence of effect modification. Chance alone can produce convincing looking subgroup effects: the ISIS-2 trial of aspirin after suspected myocardial infarction (1988) reported, as a deliberate warning, that aspirin appeared no better than placebo in patients born under Gemini or Libra. ICEMAN, the Instrument to assess the Credibility of Effect Modification Analyses (2020), helps judge a claimed subgroup effect by asking, for example, whether its direction was hypothesized in advance, whether a test for interaction suggests that chance is an unlikely explanation, and whether only a small number of effect modifiers were tested.

Conduct subgroup analyses when there is a prespecified, biologically plausible reason to expect that the treatment effect may differ across patient groups. Limit the number of subgroup analyses to maintain statistical integrity. Always test for interaction rather than comparing the significance of the treatment effect within each subgroup. Interpret subgroup findings cautiously, recognizing that many apparent subgroup effects turn out to be chance findings, and consider requiring replication in an independent study before changing clinical practice based on a subgroup result.

A common error is comparing p values across subgroups (declaring that the treatment "works" in one subgroup because p < 0.05 but "does not work" in another because p = 0.12) without performing a formal interaction test. Another mistake is conducting many post hoc subgroup analyses and presenting only those with significant findings, a form of data dredging. Defining subgroups by characteristics measured after randomization, such as treatment adherence, is a further error: the treatment itself can affect them, so comparisons within such subgroups are no longer protected by randomization. Researchers sometimes ignore the multiple comparison problem, treating each subgroup result as if it were the sole hypothesis tested. Finally, changing clinical practice based on a single, unreplicated subgroup finding is premature and risks causing harm.

A large cardiovascular outcomes trial of 18,000 patients tests a new lipid lowering drug. The prespecified analysis plan includes subgroup analyses by baseline LDL level (above versus below 130 mg/dL), age (above versus below 65 years), and diabetes status. The overall hazard ratio for major adverse cardiovascular events is 0.82 (95% CI: 0.74 to 0.91). The interaction test for diabetes status is significant (p for interaction = 0.008), with a hazard ratio of 0.68 (95% CI: 0.57 to 0.81) in diabetic patients versus 0.91 (95% CI: 0.80 to 1.03) in nondiabetic patients. The authors note this as a hypothesis generating finding that warrants a dedicated trial in the diabetic population.